
Triheptanoin (UX007) | Treatment of Mitochondrial Dysfunction in Rett Syndrome
Daniel Tarquinio, DO, MS | Center for Rare Neurological Diseases
$51,600 AWARDED
Dr. Daniel Tarquinio, the director of the Rett Syndrome Clinic in Atlanta is recruiting a 12 person, open label trial (everyone gets the drug) testing triheptanoin. The drug, also called UX007, is a colorless oil which is broken down in the body to help fuel specific chemical reactions that produce energy. Administration of UX007 has shown improvements in both metabolism and mortality in disorders with impaired energy production (for example, mitochondrial disorders). Treatment with UX007 improved longevity, motor function, and social interaction in the mouse model of Rett Syndrome, and may have improved metabolic dysfunction as well. Additionally, in general acute and chronic mouse models of epilepsy, UX007 acts as an anticonvulsant, although the mechanism for this is unclear.
The primary objective of the study is to evaluate the safety and tolerability of UX007 in individuals with Rett Syndrome using laboratory values, electrocardiogram, rate of adverse events (AE), and physical exam.
The secondary objectives are to evaluate the efficacy of UX007 in improving overall seizure frequency and dystonia (a type of movement disorder).
The study will enroll 12 pediatric, adolescent, and adult participants with Rett who have seizures (at least four seizures per month), OR dystonia (at least four dystonic episodes per month), or both. Participants must be on a stable medication regimen, defined as having had no medications added, taken away or dose adjustments for 30 days prior to the start of the study. Pediatric participants must be at least 2 years old at the time of consent, and must be in the post-regression period, defined as having had no clear loss of language or hand use in the 6 months prior to the study.
Participants will be evaluated for inclusion during a screening/baseline period of 2 months. Eligible participants will begin UX007 after 2 months using a 2-week titration schedule until the participant has reached age-specific target dosing. Once the maximum dose is reached, the participant will continue to receive UX007 for 4 months. Participants will be monitored for an additional 2-month period.
The trial is funded by Ultragenyx and RSRT.
For more information about the trial please contact Dr. Tarquinio at daniel@rareneuro.com .
Current Projects
-
A Drug-Screening Platform for the MECP2… Alysson Renato Muotri, PhD | University of California San Diego
$792,000READ MORE -
A Study to Evaluate Ketamine for the Treatment of… Clinical Trial Consortium
$1,300,000READ MORE -
Triheptanoin (UX007) | Treatment of Mitochondrial… Daniel Tarquinio, DO, MS | Center for Rare Neurological Diseases
$51,600READ MORE -
Protein Replacement for Rett Syndrome Armagen
$125,000READ MORE -
Gene Therapy Approach to Treating MECP2… Kevin Foust, PhD | Ohio State University
$40,000READ MORE -
Optimizing Gene Therapy for Rett Syndrome Kathrin Meyer, PhD
$221,004READ MORE -
A System For Dosage-independent Control of Mecp2… Michael Elowitz, PhD | Caltech
$197,681READ MORE -
Developing a pre-clinical DNA base editing program… BEAM Therapeutics
$1,870,660READ MORE -
Exploration of the Impact of Cyclodextrin on… Stephen Turley, PhD & Adam Lopez, PhD | University of Texas Southwestern…
$156,180READ MORE -
Investigating the Potential of Antisense… Huda Zoghbi, MD | Baylor College of Medicine
$530,000READ MORE -
Identification of Gene Modifiers that Ameliorate… Monica Justice, PhD | Hospital for Sick Children (Toronto)
$2,300,000READ MORE -
Identifying Therapeutics for Treating Rett… Michael Greenberg | Harvard University
$110,000READ MORE -
Development of an In-Vitro Cell System For… Q-State BioSciences
$828,141READ MORE -
Modeling MECP2 Dosage in Human Cerebral Organoids Alysson Renato Muotri, PhD | University of California San Diego
$209,000READ MORE -
RNA and Genome editing for treatment of Rett… Jonathan Watts, PhD / Eric Sontheimer, PhD / Scot Wolfe, PhD / Anastasia…
$2,403,735READ MORE -
Discovery of Compounds Promoting MECP2… Andrew Napper, PhD | Nemours/A.I. duPont Hospital for Children
$268,452READ MORE -
Reversal of Rett Phenotype: A screen for compounds… Rudolf Jaenisch, MD | Whitehead Institute
$180,000READ MORE -
A Forward Genetic Screen to Identify Druggable… Huda Zoghbi, MD | Baylor College of Medicine
$1,485,949READ MORE -
Identification of Genetic Modifiers in Rett… Jeffrey Neul, MD, PhD | University of California San Diego
$315,000READ MORE -
RNA-editing as a gene therapy approach for Rett… Guoping Feng, PhD /Feng Zhang, PhD /Robert Desimone, PhD MIT/Broad/Harvard
$2,332,000READ MORE -
New Editing Enzymes for RNA Gail Mandel, PhD | John Sinnamon, PhD
$345,000READ MORE -
From Sensory-Perceptual Representations to… John Foxe, PhD., University of Rochester, Albert Einstein College of…
$533,607READ MORE -
Treatment of Rett Syndrome with Lovastatin Aleksandra Djukic, MD, PhD Albert Einstein College of Medicine,…
$403,000READ MORE -
Is MECP2 Duplication/Triplication Syndrome… Huda Zoghbi, MD | Baylor College of Medicine
$236,000READ MORE -
Screening for drugs that can rebalance long gene… Mark Zylka, PhD | University of North Carolina at Chapel Hill
$400,000READ MORE -
New Molecular Tools for Directed Editing of MeCP2… Peter Beal, PhD | UC Davis
$563,870READ MORE -
Outlining the Autonomic Signature of Rett Syndrome Debra Weese-Mayer, MD & Michael Carroll, PhD | Ann & Robert H. Lurie…
$157,000READ MORE -
Therapeutic Approaches to Reversing Forebrain and… David Katz, PhD | Case Western Reserve University
$500,000READ MORE -
Treatment of Rett Syndrome with Copaxone Aleksandra Djukic, MD, PhD Albert Einstein College of Medicine,…
$487,000READ MORE -
PNA Nanoparticles for Gene Editing of Rett… Peter Glazer, MD, PhD & Mark Saltzman, PhD | Yale University
$275,000READ MORE -
Clinical Development of NLX-101 in Rett Syndrome;… Mark Varney, PhD | Neurolixis
$585,000READ MORE -
Systems Genetics Approach toward Understanding… Terry Magnuson, PhD | University of North Carolina at Chapel Hill
$200,000READ MORE -
Spliceosome-Mediated RNA Trans-Splicing Therapy… Stuart Cobb, PhD | University of Edinburgh
$918,475READ MORE -
High-Content Phenotypic Screening of Existing… Christopher Gibson, PhD & Dean Li, MD, PhD | Recursion Pharmaceuticals
$50,000READ MORE -
Readthrough of premature termination codons for… Allan Jacobson, PhD / Jonathan Watts, PhD | UMASS
$323,000READ MORE -
Exploring the Link Between MeCP2 and Gut… Ali Khoshnan, PhD & Sarkis K. Mazmanian, PhD | California Institute of…
$200,000READ MORE -
Testing NR2A and NR2B NAMs in the mouse models of… Michela Fagiolini, PhD | Boston Children’s Hospital
$464,336READ MORE -
Reactivation of MECP2 and CDKL5 genes by… Andrea Cerase, PhD | Queen Mary University of London
$351,022READ MORE -
Testing Whether LM22A-4 Improves Hippocampal… Lucas Pozzo-Miller, PhD | University of Alabama Birmingham
$110,000READ MORE -
Reactivation of MECP2 by Artificial Transcription… Raf Schmid, PhD, MSCR | University of Pennsylvania
$141,912READ MORE -
Preclinical Studies of LM22A-4 in Mouse Models of… David Katz, PhD | Case Western Reserve University
$272,000READ MORE -
Reactivation of MECP2 with Epigenome Editing Tools… Rudolf Jaenisch, MD | Whitehead Institute
$600,000READ MORE -
Evaluating Cell-permeant Miniature Proteins… Alanna Schepartz, PhD | Yale University
$270,216READ MORE -
Outcome Measures and Biomarkers Development Timothy Benke, MD, PhD | Aleksandra Djukic, MD, PhD | Alan Percy, MD |…
$4,500,000READ MORE -
Gene Therapy Consortium 2.0 Adrian Bird, PhD | Stuart Cobb, PhD | James Wilson, MD, PhD
$5,463,184READ MORE -
Outcome Measures and Biomarkers Development Timothy Benke, MD, PhD | Alan Percy, MD | Daniel Tarquinio, DO, MS
$4,500,000READ MORE -
MECP2 Consortium Adrian Bird, PhD | Michael Greenberg, PhD | Gail Mandel, PhD
$9,000,000READ MORE -
Clinical Trial Consortium David Lieberman & Mustafa Sahin | Eric Marsh | Jeff Neul | Alan Percy |…
$2,442,507READ MORE -
Reactivating MECP2 Consortium Ben Philpot, PhD & Bryan Roth, PhD | Antonio Bedalov, MD, PhD | Jeannie…
$6,416,072READ MORE